Ceo
CurrentOptalert is an innovative medtech company, that has pioneered the use of Blepharometry (the measurement of blinks) in the quantification of drowsiness. Optalert discovered the biomarker for drowsiness, the connection between brain function and eyelid movement. Using Artificial Intelligent techniques Optalert developed an algorithm that could quantify the level of deterioration in cognitive brain function due to drowsiness. This led to the only scientifically proven, objective measurement of drowsiness, the Johns Drowsiness Scale (JDS). The JDS is used worldwide in both research for accurately quantifying drowsiness levels and in industry, protecting thousands of lives and valuable company assets.Optalert is now turning its extensive expertise in Blepharometry and AI to identify the biomarkers for other degradations to neurological brain function such as onset of seizures due to Epilepsy, ADHD, Parkinson’s, Alzheimer’s, alertness and motor neuron disease.